Copyright
©The Author(s) 2017.
Figure 1 Overview of angiotensin receptor blockers actions on the liver.
ARBs reduce hepatic steatosis through favored beta-oxidation and reduced insulin resistance. Concomitantly, it indirectly enhances Mas receptor activity, eliciting hepatoprotective effects by low TGF-beta1 expression, which limits hepatic stellate cells activation and prevents liver fibrosis. ARBs: Angiotensin receptor blockers; TGF-beta1: Transforming growth factor-beta 1.
- Citation: Souza-Mello V. Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. World J Hepatol 2017; 9(2): 74-79
- URL: https://www.wjgnet.com/1948-5182/full/v9/i2/74.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i2.74